anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the medicine useful for preventing and treating radiation pulmonary damages, such as radiation pneumonia and radiation pulmonary fibrosis, appearing at a high rate after a chest radiation therapy. SOLUTION: The medicine for preventing and treating the radiation pulmonary damages contains (2R,4R)-4-methyl-1-[N<2> -(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)- L-arginyl]-2-piperidine carboxylic acid of the formula, its hydrate, or their salts as an active ingredient. The compound of the formula may be prepared into an oral administration agent such as tablets, capsules, powder, pills, granules, solutions or syrups or in a parenteral administration agent such as injections, intravenous drip influsions, suppositories, inhalants or plasters as such or after compounded with other additives. When intravenously administered, the medicine is administered at a does of 0.1-50mg/kg, preferably 0.4-3mg/kg, a day for an adult as the active ingredient. The medicine is preferably administered in one or several portions a day in the early period of the radiation pulmonary disease.  After the administration in the early period, the medicine is preferably administered at a rate of once per one or two weeks for several mouths to several years for the prevention of the radiation pulmonary fibrosis.
Peripheral arterial disease involving the lower limbs is becoming an increasingly important health issue which places considerable burden on individuals, communities and health care resources. PAD affects an estimated 27 million adults \>55 years of age in Europe and North America (1). The prevalence of PAD in Asia is expected to be similar and is likely to rise as the Chinese population ages. Intermittent claudication affects most patients with PAD. Although IC is not limb-threatening, the loss of walking ability and the experience of pain with ambulation can cause significant social, leisure, and occupational impairment in many patients (2-4). The decreased QoL experienced in patients with IC is on par with other cardiovascular diseases such as heart failure and heart attack. More alarmingly, physical disability is associated with higher risk of death among PAD patients. For these reasons and because patients are chronically disabled, the treatment of IC has increasingly become a major clinical focus in cardiovascular research.

For PAD patients, it is critical to focus on therapies that can reduce the underlying cardiovascular risk as well as improving functional status and Qol. Although multiple therapies (antiplatelet agents, statins, anti-hypertensive agents) have been proven to reduce cardiovascular risk in PAD patients, very few therapeutic agents have been shown to improve symptoms of IC in PAD patients (5). As such there is a large unmet need in terms of leg-specific therapies that can improve walking performance and functional capacity for this debilitating disease. Traditional Chinese herbal medicine such as Danshen and Gegen are well established in the treatment of cardiovascular diseases and well tolerated by most patients. The studies done at the Institute of Chinese Medicine of the CUHK showed particularly encouraging results (6-8). The outcomes of this study have the potential to change local and international practice in providing a novel therapeutic option in the treatment of symptomatic PAD. As parallel laboratory research is being done to identify the most active components of the D\&G formula in preparation for drug development, the efficacy of D\&G in PAD will offer more assurance for the systemic efforts.
FIELD: biotechnology, antibiotics, pharmacy. SUBSTANCE: invention relates to novel streptogramins of the formula (I)   and to method for preparing streptogramins by mutasynthesis using a mutated microorganism for alternation of biosynthesis of at least a single precursor of streptogramins. Invention describes also nucleotide sequences and polypeptides taking part in biosynthesis of these precursors. Invention describes also pharmaceutical composition based on the claimed compounds and eliciting an antibacterial activity. EFFECT: improved preparing method, valuable medicinal properties of compounds. 40 cl, 13 dwg, 5 tbl
Objective: This study aims to evaluate the predictive value of neutrophil-lymphocyte ratio (NLR) in determining infection after orthopedic surgery. Methods: A comprehensive search was conducted in PubMed, EBASE, CNKI, and Wanfang databases to identify relevant studies. The quality of the included studies was assessed using QUADAS-2. Data extraction was performed to calculate sensitivity, specificity, and other indicators. Bivariate mixed-effects meta-analysis was conducted using Stata software. The sources of heterogeneity were evaluated, and a summary receiver operating characteristic curve was generated. Results: A total of 16 literatures comprising 18 studies involving 3737 patients were included in this analysis. NLR demonstrated moderate sensitivity (0.77) and specificity (0.69) in diagnosing orthopedic post-operative infection, with an area under the curve of 0.80 and diagnostic odds ratio of 7.76. Significant heterogeneity was observed among the studies, primarily due to variations in surgical type, infection type, blood test timing, and NLR cutoff value. Fagan nomogram indicated that NLR could increase the positive posterior probability to 72% and decrease the negative posterior probability to 25%. The pooled effect of the likelihood ratio dot plot for diagnosis fell in the lower right quadrant. Deek funnel plot suggested no publication bias in this study. Conclusion: NLR holds certain value in diagnosing infection after orthopedic surgery and can provide additional information to assess the risk of infection. However, its predictive performance is influenced by various factors, and it cannot be used as a sole criterion for confirming the diagnosis. Prospective studies should be conducted in the future to optimize the diagnostic threshold and explore its combination with other indicators.
In the experimental group, participants will go through one assigned chatbot each day for 10 days, with the sequence of the assigned chatbot randomized. One group of participants will receive chatbot notifications for 10 days, another group of participants will not receive chatbot notifications. They can freely access all chatbots after the completion of post-evaluation. After completing the pre-evaluation questionnaire, they will complete 2 more sets of questionnaires, including a post-evaluation 11 days after group allocation, and a follow-up questionnaire 21 days after group allocation. All participants will be able to access the chatbot materials in an online platform after they have completed the research.
Fluticasone propionate, a component of AIRDUO RESPICLICK, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since fluticasone propionate is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of AIRDUO RESPICLICK in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose. A relationship between plasma levels of fluticasone propionate and inhibitory effects on stimulated cortisol production has been shown after 4 weeks of treatment with fluticasone propionate inhalation aerosol. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing AIRDUO RESPICLICK.

Because of the possibility of significant systemic absorption of inhaled corticosteroids, patients treated with AIRDUO RESPICLICK should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects. If such effects occur, AIRDUO RESPICLICK should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids, and for management of asthma symptoms.
The guideline update outlines the advantages as well as the limitations of NIV in the treatment of acute respiratory failure in daily clinical practice and in different indications.Non-invasive ventilation (NIV) has a high value in therapy of hypercapnic acute respiratory failure, as it significantly reduces the length of ICU stay and hospitalization as well as mortality.Patients with cardiopulmonary edema and acute respiratory failure should be treated with continuous positive airway pressure (CPAP) and oxygen in addition to necessary cardiological interventions. This should be done already prehospital and in the emergency department.In case of other forms of acute hypoxaemic respiratory failure with only mild or moderately disturbed gas exchange (PaO2/FiO2 > 150 mmHg) there is no significant advantage or disadvantage compared to high flow nasal oxygen (HFNO). In severe forms of ARDS NIV is associated with high rates of treatment failure and mortality, especially in cases with NIV-failure and delayed intubation.NIV should be used for preoxygenation before intubation. In patients at risk, NIV is recommended to reduce extubation failure. In the weaning process from invasive ventilation NIV essentially reduces the risk of reintubation in hypercapnic patients. NIV is regarded useful within palliative care for reduction of dyspnea and improving quality of life, but here in concurrence to HFNO, which is regarded as more comfortable. Meanwhile NIV is also recommended in prehospital setting, especially in hypercapnic respiratory failure and pulmonary edema.With appropriate monitoring in an intensive care unit NIV can also be successfully applied in pediatric patients with acute respiratory insufficiency.
The invention discloses a bisabolane sesquiterpenoid, a preparation method thereof and application thereof as a selective antibacterial agent. The method comprises the following steps of: performing strain culturing on a sponge endophytic fungi, i.e. Asergillus sp. (HM565949) in a strain medium; cultivating the fungi by fermenting in a fermentation medium; filtering the obtained fermentation broth to remove thallus, concentrating the filtrate, and extracting the filtrate with ethyl acetate; and performing chromatographic separation on the concentrate and respectively concentrating the obtained eluent to obtain white powder, i.e. the aspergterpeinoid A, aspergiterpenoid C and aspergiterpenoid D. The bisabolane sesquiterpenoid obtained from a marine fungi can selectively inhibit the activities of Staphylococcus albus, Bacillus subtilis, Bacillus cereus, Sarcina lutea, Escherichia coli, Micrococcus tetrgenus, marine bacterial Vibrio parahaemolyticus and marine bacterial Vibrio anguillarum, and can be used for developing the selective antibacterial agent. In addition, the raw materials can be massively produced and are free of the limitation of resources. Therefore, the bisabolane sesquiterpenoid has wide application prospect.
Non-treatment seeking individuals meeting criteria for alcohol dependence (N=30) will be recruited through advertisement and paid for their participation. Alcoholics, after baseline evaluation, will be assigned through urn randomization to one of two experimental groups in which they will receive either aripiprazole (up to 15 mg/day) or an identical placebo. Subjects will take the study drug or placebo for 8 days (day 1-6 being the natural observation period). After a minimum of 24 hours of abstinence from alcohol (day 7-8) they will undergo an alcohol administration (priming dose) and motivated free choice drinking procedure (on day 8). Alcoholic subjects will receive a brief counseling session at the end of the study to enhance their awareness of problem drinking and to motivate them to seek treatment. Referral for treatment will be offered.

Each subject will undergo a functional MRI brain scan with cue stimulation on day 7, on the evening before the alcohol administration paradigm. fMRI brain imaging technology will be used to determine if alcoholics treated with aripiprazole differ in alcohol cue-induced activity in the nucleus accumbens. It is hypothesized that aripiprazole will reduce nucleus accumbens activation to alcohol cues compared to placebo.
The decision system includes a dynamic biomedical map configured to provide a plurality of functions. By dynamic change of the biomedical graph structure, a better separation of a set of different inputs can be identified. The decision making process to reach a conclusion may be considered as a path through the biomedical map. This approach illustrates how and why a particular conclusion is reached, as compared to a typical "black box" neural network. Such elucidation may lead to the identification of new and/or unexpected relationships between input data and resulting conclusions, and also provide confidence that the conclusions are based on a rational decision process. As an example, the decision system is applied to medical decisions made In Vitro Fertilization (IVF).
In this clinical study, a design was chosen to reflect European standards recommended by EULAR for treatment of active RA by comparison of a Treat-to- target (T2T) approach in two treatment groups: Patients with active RA and lack of efficacy of at least one csDMARD treatment will be randomized to receive either TOFA or ETA. The study will be separated into two parts: The capability to decrease and discontinue pain-reducing treatment with a NSAID (Celecoxib, two times 200 mg as maximum standard dosage for RA) over the first 12 weeks of treatment will be measured for primary outcome. The proportion of patients with successful discontinuation of Celecoxib and significant and clinical relevant decrease of pain-levels measured using a visual analogue scale (VAS) with a reduction of at least 30% at week 12 compared to baseline will be compared between the two treatment groups.

Starting at week 12, the capability to taper CS treatment using a treat-to-target strategy, i.e. when at least low disease activity (LDA-DAS28) is achieved, will be measured in both groups. In addition to efficacy assessments (DAS28, ACR-response, SJC, TJC), patient reported outcomes, Quality of Life (QoL) measurements and patient satisfaction will be evaluated. Safety (severity and frequency of adverse events) will be evaluated over the 24-week treatment period.
Undergraduate students who reported high to moderate food insecurity, are at least 18 years of age, speak English, and plan to return to the University at Buffalo campus in Spring 2025 will receive weekly fruit and vegetable incentives encouraging them to shop at the UB Veggie Van (intervention). They will complete incentivized data collection after 13 weeks of the intervention (incentives/access to UB Veggie Van).
Susac syndrome (SuS) presents with encephalopathy, visual disturbances, and hearing loss from immune-mediated microvascular occlusion. While acute SuS is well-described, long-term cognitive outcomes with current treatments are underknown. We assessed ten SuS patients treated in accordance with evidence-based guidelines using immunotherapies targeting humoral and cell-mediated pathways. Patients were followed for a median 3.6 years. Initially, cognition inversely correlated with corpus callosum lesions on MRI. All reported cognitive improvement; 5/10 patients had residual deficits in visual attention and executive function. Early, aggressive treatment was associated with good outcomes; extensive early corpus callosum lesions may identify patients at-risk of persistent cognitive deficits.
FIELD: biotechnology, genetic engineering. SUBSTANCE: BDNF protein eliciting the neutropic activity is obtained by mammal cells culturing, in part, cells of the strain COS transformed with an expression vector PCMYI-PBDNF. Vector contains DNA fragment encoding the indicated protein. Nucleotide sequence of human, rat, pig and chicken DNA fragment is determined. BDNF protein has molecular mass 12 kDa, isoelectric point 9.9 and able to support viability of oral radix neuron ganglions, dopaminergic and cholinergic central nervous system neurons and inhibit the differentiation of astroglial cells. BDNF protein can be used for diagnosis and treatment of patients with different neurological disorders. EFFECT: improved method of protein preparing. 6 cl, 37 dwg, 12 tbl, 20 ex
PROBLEM TO BE SOLVED: To obtain a medicine for suppressing ageing of brain such as Alzheimer's disease by including a specific organogermanium compound as an active ingredient. SOLUTION: This medicine is obtained by including an organogermanium compound shown by the formula [R1 -R3 are each H, methyl, ethyl, etc.; X is OH, an O-lower alkyl, etc.], as an active ingredient. The medicine can be administered orally, parenterally, or locally. The medicine can be prepared, for example, in (A) tablet, powder, or capsule for oral administration, (B) injection for parenteral administration, or (C) lotion or ointment for topical application. The content of the organogermanium compound can be, for example, 5-500 mg per administration unit as needed. The dose of the compound can be, for example, 1-100 mg/kg.d or so depending on the condition and so on.
BACKGROUND: Within North America and worldwide, drug related overdoses have increased dramatically over the past decade. COVID-19 escalated the need for a safer supply to replace unregulated substances and to reduce toxicity and overdoses. Service providers play an integral role in the delivery of safer supply but there is little empirical evidence that conceptualizes effective safer supply from their perspectives. This study explored early implementation and impacts of a safer supply program, capturing the perspectives of an interdisciplinary team of service providers on tensions and issues encountered in the development of the SAFER program.
METHODS: Using a community-based participatory approach, we conducted individual interviews with program providers (n = 9). The research team was composed of researchers from a local drug user organization, a local harm reduction organization, and academic researchers. The Consolidated Framework for Implementation Research (CFIR) informed the interview guide. Data was analyzed using thematic analysis.
RESULTS: There are six themes describing early implementation: (1) risk mitigation prescribing as context for early implementation; (2) developing SAFER specific clinical protocols; (3) accessibility challenges and program innovations; (4) interdisciplinary team and wraparound care; (5) program tensions between addiction medicine and harm reduction; (6) the successes of safer supply and future visions.
CONCLUSION: Early implementation issues and tensions included prescriber concerns about safer supply prescribing in a highly politicized environment, accessibility challenges for service users such as stigma, encampment displacement, OAT requirements, program capacity and costs, and tensions between addiction medicine and harm reduction. Navigating these tensions included development of clinical protocols, innovations to reduce accessibility challenges such as outreach, wraparound care, program coverage of medication costs and prescribing safer supply with/without OAT. These findings contribute important insights for the development of prescribed safer supply programs.
The present invention includes a dosage form that facilitates the controlled release of an active agent at a desired release rate or release rate profile. In each embodiment, the dosage form of the present invention includes a bi-layer membrane system and an osmotic core. The bi-layer membrane system includes a semipermeable membrane and an osmosensitive membrane and forms an internal compartment that is occupied by the osmotic core. The osmotic core of the dosage form of the present invention includes and active agent composition and a light push layer. The dosage form of the present invention additionally includes a passageway that is formed through the bi-layer membrane system and permits expulsion of the active agent composition from the dosage form during operation. The bi-layer membrane system and the osmotic core of the dosage form of the present invention are formulated and formed to provide controlled release of the active agent included in the active agent composition of the osmotic core, while simultaneously facilitating increased loading of active agent within a dosage form of given dimension and increasing the delivery efficiency of such active agent relative to prior osmotic dosage forms including a push layer.
The invention provides the methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacterioclorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalies that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging.
A device for treating the viral hepatitides with the aid of medicinal ozone contains the appliances for blood collection and return (catheter, injection needle), the tubes for the movement of the fluid with flow rate controller, the peristaltic pump, the dialyzer, the source of ozone and medical oxygen. The device also contains two containers – the first container for the mixture of physiologic saline and heparin and the second one for ozonized physiologic saline, the unit for mixing the blood and the ozonized physiologic saline with built-in filter. The second peristaltic pump is connected to the control unit of the first peristaltic pump. The first container is connected to the tube connecting the appliance for collection of the blood with the first peristaltic pump. The lower central pipe of the dialyzer is connected to the first peristaltic pump. Its upper central pipe is connected to the rotor-film contactor set in motion with the aid of the drive. The lower pipe of the dialyzer is connected to the containers for collected plasma. The rotor-film contactor is connected to carbohemofilter via the second peristaltic pump. The third pipe of the rotor-film contactor is connected to the outlet of ozone source, the latter being connected to the oxygen source. The upper pipe of carbohemofilter is connected to the mixing unit with built-in filter and the appliance for returning the blood to the patient. The mixing unit with built-in filter is connected to the container with physiologic saline intended for the assisting heparinization.